Medicament comprising HGF gene

ABSTRACT

The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively exhibited, resulting in minimizing the side effects of HGF.

TECHNICAL FIELD TO WHICH THE INVENTION PERTAINS

[0001] The present invention relates to a medicament for use in the genetherapy and the like. More particularly, the present invention relatesto a medicament comprising a hepatocyte growth factor (HGF) gene as wellas a liposome containing the HGF gene.

PRIOR ARTS

[0002] HGF is a physiologically active peptide that exhibit diversepharmacological activities. The pharmacological activities of HGF aredescribed in, e.g., JIKKEN-IGAKU (Experimental Medicine), Vol. 10, No. 3(extra issue), 330-339 (1992). In view of its pharmacologicalactivities, HGF is expected to be useful as a drug for the treatment ofliver cirrhosis or renal diseases; epithalial cell growth accelerators;anticancer agents; agents for the prevention of side effects in cancertherapy; agents for the treatment of lung disorders, gastrointestinaldamages or cranial nerve disorders; agents for the prevention of sideeffects in immunosuppression; collagen degradation accelerators; agentsfor the treatment of cartilage disorders, arterial diseases, pulmonaryfibrosis, hepatic diseases, blood coagulopathy, plasma hypoproteinosisor wounds; agents for the improvement of nervous disorders;hematopoietic stem cell potentiators; and hair growth promoters(Japanese Patent KOKAI (Laid-Open) Nos. 4-18028 and 4-49246, EP 492614,Japanese Patent KOKAI (Laid-Open) No. 6-25010, WO 93/8821, JapanesePatent KOKAI (Laid-Open) Nos. 6-172207, 7-89869 and 6-40934, WO 94/2165,Japanese Patent KOKAI (Laid-Open) Nos. 6-40935, 6-56692 and 7-41429, WO93/3061, Japanese Patent KOKAI (Laid-Open) No. 5-213721, etc.).

[0003] As to gene therapy, extensive studies and investigations havebeen currently made all over the world for adenosine deaminasedeficiency, AIDS, cancer, pustulous fibrosis or hemophilia, etc.

[0004] However, gene therapy using the HGF genes is unknown yet. It iseven unclear if such gene therapy is effectively applicable.

[0005] Problems to be Solved by the Invention

[0006] HGF is known to be one of the drugs that have a short half lifein blood. As a natural consequence, persistent topical administrationhas been desired for HGF.

[0007] In view of the diverse pharmacological activities of HGF, HGF isexpected to be developed as a drug having extended applications tovarious diseases. On the other hand, when HGF is systemicallyadministered, side effects might be caused due to the diversepharmacological activities of HGF. In addition, when HGF itself isintravenously administered, HGF encounters such a drawback that aconsiderable amount of HGF is retained in the liver, resulting inreduction of the amount of HGF to reach the target organ.

[0008] Means for Solving the Problems

[0009] The present invention has been made to solve the foregoingproblems. In summary, the present invention relates to:

[0010] (1) a medicament comprising a HGF gene;

[0011] (2) a liposome containing the HGF gene;

[0012] (3) a liposome according to (2), which is a membrane fusionliposome fused to Sendai virus; (4) a medicament comprising the liposomeaccording to (2) or (3); (5) a medicament according to (1) or (4), foruse in the treatment for arterial disorders; and, (6) a medicamentaccording to (1) or (4), for use in the treatment for cartilageinjuries.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013]FIG. 1 shows an expression of HGF in rat coronary endothelialcells sensitized with the hemagglutinating virus of Japan(HVJ)-liposome-DNA in Test Example 1.

[0014] In FIG. 2, the (line) graph shows a cell growth rate in thepresence or absence of HGF from the HVJ-liposome-cont-sensitizedendothelial cells in Test Example 2, wherein “DSF” designates a group ofthe endothelial cells sensitized with HVJ-liposome-cont and “HGF”designates a group incubated in the presence of recombinant human HGF ina predetermined concentration. The bar in FIG. 2 shows a cell growthrate of the HVJ-liposome-DNA-sensitized endothelial cells in TestExample 2, wherein “DSF” designates a group of the endothelial cellssensitized with HVJ-liposome-cont and “HGF vector” designates a group ofthe endothelial cells sensitized with HVJ-liposome-DNA.

[0015]FIG. 3 shows a cell growth rate of endothelial cells sensitizedwith HVJ-liposome-DNA in the presence or absence of anti-HGF antibody inTest Example 2, wherein “control” represents a group of theHVJ-liposome-cont-sensitized endothelial cells incubated in the presenceof IgG control; “HGF” represents a group of theHVJ-liposome-DNA-sensitized endothelial cells incubated in the presenceof IgG control; and “HGFab” represents a group of theHVJ-liposome-DNA-sensitized endothelial cells incubated in the presenceof a rabbit anti-human HGF antibody. The cell growth rate (%) isexpressed in terms of relative % when the growth rate in the controlgroup is made 100.

[0016]FIG. 4 is a graph showing the cell growth effect of the culturesupernatant from the HVJ-liposomeDNA-sensitized rat vascular smoothmuscle cells (hereinafter often abbreviated as VSMCs) on rat coronaryendothelial cells in Test Example 3, wherein “control” designates agroup added with the culture supernatant from theHVJ-liposome-cont-sensitized rat VSMCs, and “HGF” designates a groupadded with the culture supernatant from the HVJ-liposome-DNA-sensitizedrat VSMCs.

[0017]FIG. 5 is a graph showing the results in Test Example 3 in whichthe concentration of HGF in the supernatant from the incubatedHVJ-liposome-DNA-sensitized rat VSMCs was determined using theanti-human HGF antibody. In the figure, “no-treatment” represents agroup of the culture supernatant of non-sensitized VSMCs; “control”represents a group of the supernatant from the incubatedHVJ-liposome-cont-sensitized rat VSMCs; and “HGF” represents a group ofthe supernatant from the incubated HVJ-liposome-DNA-sensitized ratVSMCs.

[0018]FIG. 6 is a graph showing the results in Test Example 3 in whichthe concentration of HGF in the supernatant from the incubatedHVJ-liposome-DNA-sensitized rat VSMCs was determined using the anti-ratHGF antibody. In the figure, “no-treatment” represents a group of theculture supernatant of non-sensitized VSMCs; “control” designates agroup of the supernatant from the incubated HVJ-liposome-cont-sensitizedrat VSMCs; and “HGF” designates a group of the supernatant from theincubated HVJ-liposome-DNA-sensitized rat VSMCs.

[0019]FIG. 7 is a graph showing the cell growth effect of thesupernatant from the incubated HVJ-liposome-DNA-sensitized rat coronaryendothelial cells on rat coronary endothelial cells in Test Example 4,wherein A, B and C designate, respectively, a group added with thesupernatant of the incubated HVJ-liposome-DNA-sensitized rat coronaryendothelial cells, a group added with the supernatant of the incubatedHVJ-liposome-cont-sensitized rat coronary endothelial cells, and a groupof no-treatment animals.

[0020]FIG. 8 shows the cell growth effect of HVJ-liposome-DNA-sensitizedrat coronary endothelial cells on rat coronary endothelial cells in thepresence of an anti-HGF antibody in Test Example 4. In the figure, Arepresents a group added with the supernatant from the incubatedHVJ-liposome-DNA-sensitized rat coronary endothelial cells; B representsa group added with the supernatant from the incubatedHVJ-liposome-cont-sensitized rat coronary endothelial cells; Crepresents a group added with the anti-HGF antibody to the supernatantfrom the incubated HVJ-liposome-DNA-sensitized rat coronary endothelialcells; and D represents a group added with the control antibody to thesupernatant of the incubated HVJ-liposome-DNA-sensitized rat coronaryendothelial cells.

[0021]FIG. 9 is a drawing showing the cell growth of endothelial cellsin Test Example 5 when HVJ-liposomeDNA-sensitized human VSMCs wereco-incubated with non-sensitized human endothelial cells. In the figure,“control” represents a group co-incubated withHVJ-liposome-cont-sensitized VSMCs, and “HGF” represents a group of thesupernatant from the incubated HVJ-liposome-DNA-sensitized VSMCs.

[0022]FIG. 10 indicates the cell growth of endothelial cells in TestExample 6 when HVJ-liposomeDNA-sensitized rat VSMCs were co-incubatedwith non-sensitized rat coronary endothelial cells. In the figure,“control” represents a group co-incubated with theHVJ-liposome-cont-sensitized VSMCs, and “HGF” represents a group of theculture supernatant of the HVJ-liposome-DNA-sensitized VSMCs.

[0023]FIG. 11 shows an increase in the number of minute blood vessels inrat heart muscle directly injected with HVJ-liposome-DNA in Test Example8, wherein “HGF” denotes the number of minute blood vessels in rat heartmuscle directly injected with HVJ-liposome-DNA, and “control” denotesthe number of minute blood vessels in rat heart muscle directly injectedwith HVJ-liposome-cont.

[0024]FIG. 12 is a drawing showing that 3 weeks after administration ofHVJ-liposome-DNA into the joint, development of cartilage-like cells wasnoted in Test Example 9, in which the synthesis of ToluidineBlue-stained proteoglycan was observed.

[0025]FIG. 13 is a drawing showing that 4 weeks after administration ofHVJ-liposome-DNA into the joint, development of cartilage-like cells wasnoted in Test Example 9, in which the synthesis of ToluidineBlue-stained proteoglycan was observed.

[0026]FIG. 14 is a drawing showing that even 4 weeks afteradministration of HVJ-liposome-DNA (TGF-β) prepared in ComparativeExample 2 into the joint, such development of cartilage-like cells asobserving-Toluidine Blue-stained proteoglycan synthesis was not noted inTest Example 9.

[0027]FIG. 15 is a drawing showing that even 4 weeks afteradministration of HVJ-liposome-cont prepared in Comparative Example 1into the joint, no such development of cartilage-like cells as observingToluidine Blue-stained proteoglycan synthesis was noted in Test Example9.

BEST MODE FOR CARRYING OUT THE INVENTION

[0028] The “HGF gene” employed in the present invention indicates a genecapable of expressing HGF. Thus, so long as a polypeptide expressed hassubstantially the same effect as that of HGF, the HGF gene may have apartial deletion, substitution or insertion of the nucleotide sequence,or may have other nucleotide sequence ligated therewith at the5′-terminus and/or 3′-terminus thereof. Typical examples of such HGFgenes include HGF genes as described in Nature, 342, 440 (1989),Japanese Patent KOKAI (Laid-Open) No. 5-111383, Biohem. Biophys. Res.Commun., 163, 967 (1989), etc. These genes may be used in the presentinvention.

[0029] The HGF gene is incorporated into an appropriate vector and theHGF gene-bearing vector is provided for use. For example, the HGF genemay be used in the form of a viral vector having the HGF gene asdescribed hereinafter, or in the form of an appropriate expressionvector having the HGF gene.

[0030] The “pharmaceutical composition” used in the present inventionindicates a medicament for the treatment or prevention of humandiseases, which is attributed to the pharmacological activities of HGF.For example, exemplified are medicaments for the treatment or preventionof the diseases given hereinabove.

[0031] According to the present invention, the HGF gene is introducedinto cells wherein HGF is expressed in those cells to exhibit thepharmacological actions. Thus, the medicament of the present inventionis effectively applicable to the diseases for which HGF itself iseffective.

[0032] Where the HGF gene is introduced into, e.g., cells, the growth ofvascular endothelial cells is accelerated, while undesired growth ofvascular smooth muscle cells is not accelerated, as demonstrated in theExamples hereinafter. Moreover, as demonstrated in the Examplehereinafter, where the HGF gene is introduced into the heart in vivoanimal test using rats, angiogenesis is observed. Therefore, the HGFgene is effective for the treatment and prevention of arterialdisorders, in particular, various diseases caused by disturbance whichmainly involves abnormal proliferation of vascular smooth muscle cells(e.g., restenosis after percutaneous transluminal coronary angioplasty(PTCA), arteriosclerosis, insufficiency of peripheral circulation,etc.), and for the treatment and prevention of diseases such asmyocardial infarction, myocardia, peripheral angiostenosis, cardiacinsufficiency, etc. HGF itself is also useful for the treatment andprevention of the diseases as described above, since HGF promotes theproliferation of vascular endothelial cells but does not promote thegrowth of vascular smooth muscle cells. The pharmacological effects ofthe HGF gene are attributed to those of HGF itself.

[0033] As demonstrated in the Examples hereinafter, introduction of theHGF gene into the joint results in promoting repair of articularcartilage cells thereby to promote the proliferation ofproteoglycan-synthesizing cells. Therefore, the HGF gene is effectivefor the prevention and treatment of various cartilage injuries such asosteogenetic abnormality, arthritis deformans, discopathy deformans,fracture repair and restoration insufficiency, trauma caused bysporting, key puncher's disease, etc. HGF itself is useful for thetreatment and prevention of the diseases described above, since HGFpromotes repair and growth of cartilage cells. The effects of the HGFgene are based on those of HGF itself.

[0034] “Liposome” is a closed vesicle of lipid bilayer encapsulating anaqueous compartment therein. It is known that the lipid bilayer membranestructure is extremely similar to biological membranes. To prepare theliposomes of the present invention, phospholipids are employed. Typicalexamples of phospholipids are phosphatidylcholines such as lecithin,lysolecithin, etc.; acidic phospholipids such as phosphatidylserine,phosphatidylglycerol, phosphatidylinositol, phosphatidylic acid, etc.;or phospholipids obtained by replacing an acyl group(s) of these acidicphospholipids with lauroyl, myristoyl, oleoyl, etc.; andsphingophospholipids such as phosphatidylethanolamine, sphingomyelin,etc. Neutral lipids such as cholesterol may also be added to thesephospholipids. The liposomes may be prepared, in a conventional manner,from naturally occurring materials such as lipids in normal cellmembranes. The liposomes containing the HGF gene of the presentinvention may be prepared, for example, by suspending a thin layer ofpurified phospholipids in a solution containing the HGF gene and thentreating the suspension in a conventional manner such asultra-sonication.

[0035] The liposomes containing the HGF gene of the present inventionmay be appropriately fused to viruses, etc. to form membrane fusionliposomes. In this case, it is preferred to inactivate viruses, e.g.,through ultraviolet irradiation, etc. A particularly preferred exampleof the membrane fusion liposome is a membrane fusion liposome fused withSendai virus (hemagglutinating virus of Japan: HVJ). The membrane fusionliposome may be produced by the methods as described in NIKKEI Science,April, 1994, pages 32-38; J. Biol. Chem., 266 (6), 3361-3364 (1991),etc. In more detail, the HVJ-fused liposome (HVJ-liposome) may beprepared, e.g., by mixing purified HVJ inactivated by ultravioletirradiation, etc. with a liposome suspension containing the HGF genevector, gently agitating the mixture and then removing unbound HVJ bysucrose density gradient centrifugation. The liposomes may be bound tosubstances having an affinity to target cells, thereby to enhance anefficiency of gene introduction into the target cells. Examples of thesubstances having an affinity to the target cells include ligands suchas an antibody, a receptor, etc.

[0036] For introduction of the HGF gene into cells, conventional methodsare employed, which are roughly classified into introduction via viralvectors and other strategies (NIKKEI Science, April, 1994, pages 20-45;GEKKAN YAKUJI, 36 (1), 23-48 (1994) and references cited therein). Bothmethods are available for the preparation of the medicament of thepresent invention.

[0037] The former method using viral vectors comprises the step ofincorporating the HGF gene into, e.g., a retrovirus, an adenovirus, anadeno-related virus, a herpes virus, a vaccinia virus, a poliovirus, asindbis virus or other RNA viruses. Of these viruses, a retrovirus, anadenovirus and an adeno-related virus are particularly preferablyemployed for the introduction.

[0038] Examples of the other methods include the liposome method,lipofectin method, microinjection method, calcium phosphate method,electroporation method. Of these methods, particularly preferred is theliposome method.

[0039] For practical use of the HGF gene as a medicament, it isadvantageous to introduce the HGF directly into the body (in vivomethod). Alternatively, certain cells are collected from human, the HGFgene is then introduced into the cells outside the body and the HGFgene-introduced cells are returned to the body (ex vivo method). Thesemethods are described in NIKKEI Science, April, 1994, pages 20-45;GEKKAN-YAKUJI, 36 (1), 23-48 (1994) and references cited therein. Any ofthese methods are suitably chosen depending upon a disease to betreated, target organs, etc. and applied to the medicament compositionsof the present invention.

[0040] The in vivo method is less costly, less laborious and thereforemore convenient than the ex vivo method, but the latter method providesa higher efficiency of introduction of the HGF gene into cells.

[0041] Where the medicament of the present invention is administered bythe in vivo method, the medicament may be administered through any routeappropriate for diseases to be treated, target organs, etc. Themedicament may be administered intravenously, intraarterially,subcutaneously, intramuscularly, etc., or directly to the objectiveorgan of diseases, e.g., kidney, liver, lung, brain, nerve, etc. Directadministration to the objective site can treat the target organselectively. For example, in gene therapy using a gene for restenosisafter PTCA, the composition may be administered intraarterially(JIKKEN-IGAKU, 12 (extra issue 15), 1298-1933 (1994). Preferably, themedicament of the present invention is applied at the tip of a balloonused for PTCA and rubbed the tip against blood vessel, whereby themedicament may be introduced directly into vascular endothelial cellsand vascular smooth muscle cells.

[0042] Where the ex vivo method as described above is used to introducethe HGF gene, human cells (e.g., lymphocytes or hematopoietic stemcells) are harvested in a conventional manner and the harvested cellsare sensitized with the medicament of the present invention for geneintroduction. Thereafter the HGF-producing cells are inserted back tohuman.

[0043] Where the medicament is administered by the in vivo method, themedicament may take various preparation forms, including the form ofliquid preparation. In general, the medicament may be preferablyprepared into an injection comprising the HGF gene as an activeingredient. If necessary and desired, conventional carriers may be addedto the composition. The injection may be prepared in a conventionalmanner, e.g., by dissolving the HGF gene in an appropriate solvent(e.g., sterilized water, a buffered solution, a physiological salinesolution, etc.), filtering the solution through a filter, etc. forsterilization, filling up the solution in a sterile container. Themedicament may be prepared using the HGF gene-incorporated viral vector,instead of the HGF gene itself. Where the liposomes containing the HGFgene embedded therein (or HVJ-liposomes) are employed, the medicamentmay be in the form of liposome preparations such as a suspension, afrozen preparation, a centrifugally concentrated frozen preparation,etc.

[0044] The content of the HGF gene in the medicament may beappropriately varied depending upon diseases to be treated, targetorgans, patients' ages or body weights, etc. However, it is appropriateto administer in a dose of 0.0001 mg to 100 mg, preferably 0.001 mg to10 mg when calculated as the HGF gene. The dose may be divided intoseveral days or a few months.

EXAMPLES

[0045] Hereinafter the present invention will be described in moredetail with reference to the examples but is not deemed to be limitedthereto. Materials and methods used in the following examples areoutlined below.

[0046] Materials and Methods

[0047] (1) HGF Expression Vector

[0048] The HGF expression vector was prepared by inserting human HGFcDNA (2.2 kb, Biochem. Biophys. Res. Commun., 172, 321-327 (1990);Japanese Patent KOKAI (Laid-Open) No. 5-111383) between the EcoRI andNotI sites of pUC-SRα expression vector (FEBS, 333, 61-66 (1993)). Inthis plasmid vector, transcription of HGF cDNA is regulated by SRapromoter (Nature, 342, 440-443 (1989)).

[0049] (2) Cell culture

[0050] Rat coronary endothelial cells were isolated from theenzymatically digested heart of 8 weeks aged Sprague-Dawley (SD) rats bydensity gradient centrifugation (Transplantation, 57, 1653-1660 (1994)).Rat aortic vascular smooth muscle cells (VSMCs) were obtained from 12weeks aged SD rats by enzymatic treatment (J. Clin. Invest., 93, 355-360(1994)). These cells were maintained in DMEM medium supplemented with10% (vol/vol) calf fetal serum, penicillin (100 U/ml) and streptomycin(100 μg/ml). The cells were incubated at 37° C. in a humidified 95%air-5% CO₂ atmosphere. The culture medium was routinely changed at 2day-intervals. Both immunopathological and morphological observationrevealed that these cells were endothelial cells and smooth musclecells, respectively.

[0051] Human aortic endothelial cells (five passages) and human VSMCs(five passages) were obtained from Kurabo Co. The endothelial cells wereincubated in a manner similar to the above method in MCDB131 mediumsupplemented with 5% calf fetal serum, epidermal growth factor (10ng/ml), basic fibroblast growth factor (2 ng/ml) and dexamethasone (1μM).

[0052] Endothelial cells in the stationary state were prepared accordingto the method described in J. Clin. Invest., 86, 1690-1697 (1990),ibid., 94, 824-829 (1994).

[0053] (3) Transfection of the HGF Gene into HVJ-Liposomes In Vitro

[0054] Endothelial cells or VSMCs were inoculated for sensitization on a6-well plate in a cell count of 10⁶ and proliferated to reach 80%confluence. The cells were washed 3 times with a balanced salt solution(137 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6; hereinafterabbreviated as “BSS”) supplemented with 2 mM calcium chloride. To thecells was added 1 ml of a solution of the HVJ-liposome-DNA (containing2.5 mg of lipids and 10 mg of the embedded DNA) obtained in Example 1hereinafter or 1 ml of a solution of the HVJ-liposome-cont obtained inComparative Example 1 hereinafter. The resulting mixture was incubatedat 4° C. for 5 minutes and at 37° C. for further 30 minutes. The cellswere washed and maintained in a fresh medium containing 10% bovine serumin a CO₂ incubator.

[0055] (4) Assay for the HGF Concentrations in Endothelial Cells andVSMCs

[0056] The concentration of HGF produced from the sensitized endothelialcells and VSMCs was assayed by ELISA. That is, rat or human endothelialcells or VSMCs were inoculated on a 6-well plate (made by Corning) in acell density of 5×10⁴ cells/cm², followed by incubation for 24 hours.The medium was replenished 24 hours after the sensitization, andincubation was continued for further 48 hours. To investigate if HGF wasreleased, the sensitized cells (48 hours after sensitization) werewashed and added to 1 ml of a serum-free medium containing 5×10⁻⁷ Minsulin, 5 μg/ml transferrin and 0.2 mM ascorbate. After 24 hours, theculture media were collected, centrifuged at 600 g for 10 minutes andthen stored at −20° C.

[0057] The HGF concentration in the media was determined by an enzymeimmunoassay using an anti-rat HGF antibody or an anti-human HGF antibody(Exp. Cell Res., 210, 326-335 (1994); Jpn. J. Cancer Res., 83, 1262-1266(1992)). A rabbit anti-rat or an anti-human HGF IgG was coated onto a96-well plate (made by Corning) at 4° C. for 15 hours. After blockingwith 3% bovine serum albumin-containing PBS (phosphate buffered saline),the culture medium was added to each well, and incubation was performedat 25° C. for 2 hours. After washing each well 3 times with PBScontaining 0.025% Tween (PBS-Tween), a biotinated rabbit anti-rat HGFIgG or an anti-human HGF IgG was added to each well followed byincubation at 25° C. for 2 hours. After washing with PBS-Tween, eachwell was incubated together with horse radish peroxidase-boundstreptoavidin-biotin complex (PBS-Tween solution). The enzymaticreaction was initiated by adding thereto a substrate solution(containing 2.5 mM o-phenylenediamine, 100 mM sodium phosphate, 50 mMcitrate and 0.015% hydrogen peroxide). The reaction was terminated byadding 1 M sulfuric acid to the system. Absorbance was measured at 490nm. The anti-human HGF antibody is cross-reactive only with human HGFbut not with rat HGF. The anti-rat HGF antibody is cross-reactive solelywith rat HGF but not with human HGF.

[0058] (5) HGF

[0059] The human and rat recombinant HGFs employed were purified fromthe culture solution of CHO cells or C-127 cells transfected with anexpression plasmid bearing human or rat HGF cDNA (Cell, 77, 261-271(1994); J. Clin. Invest., 93, 355-360 (1994)).

[0060] (6) Statistical Analysis

[0061] All runs were repeated at least 3 times. Data measured are shownby mean±standard error. Statistical analysis of the measured data wasmade according to the Duncan's test.

[0062] (7) Hematoxylin-Eosin (HE) Staining and Azan Staining

[0063] Ten days after the gene introduction, the HGF gene-introducedrats were sacrificed by perfusion with heparinized physiological saline.Fixation was then made overnight with a 4% paraformaldehyde PBSsolution. After fixation, the tissue was embedded in paraffin. Slideswere prepared and stained with HE and Azan in a conventional manner. Theslides were examined on a microscope to count the number ofmicrovessels.

Example 1

[0064] Preparation of HVJ-Liposomes Containing the HGF Expression Vector

[0065] Phosphatidylserine, phosphatidylcholine and cholesterol weremixed with tetrahydrofuran in a weight ratio of 1:4.8:2. By distillingtetrahydrofuran off through a rotary evaporator, the lipid mixture (10mg) was precipitated onto the container wall. After 96 μg of highmobility group (HMG) 1 nuclear protein purified from bovine thymus wasmixed with a BBS (200 μl) solution of plasmid DNA (300 μg) at 20° C. foran hour, the mixture was added to the lipid mixture obtained above. Theresulting liposome-DNA-HMG 1 complex suspension was mixed with a vortex,ultrasonicated for 3 seconds and then agitated for 30 minutes.

[0066] The purified HVJ (strain Z) was inactivated by UV irradiation(110 erg/mm² sec) for 3 minutes immediately before use. BSS was added toand mixed with the liposome suspension (0.5 ml, containing 10 mg of thelipids) obtained above and HVJ (20,000 hemagglutinating units) to makethe whole volume 4 ml. The mixture was incubated at 4° C. for 10 minutesand gently agitated at 37° C. for further 30 minutes. The unreacted HVJwas removed from the HVJ-liposomes by sucrose density gradientcentrifugation. That is, the upper layers in the sucrose densitygradient were collected to give the HVJ-liposomes containing the HGFexpression vector (containing 10 μg/ml of the HGF expression vector).The HVJ-liposomes containing the HGF expression vector is hereinafteroften referred to as HVJ-liposome-DNA.

Example 2

[0067] Administration of the HVJ-Liposome Containing the HGF ExpressionVector to Rats

[0068] The HVJ-liposomes containing the HGF expression vector wereprepared by the method as described in the above Example, using 64 μg ofHMG 1 nuclear protein and 200 μg of plasmid DNA. BSS was added to andmixed with the liposome suspension (0.5 ml, containing 10 mg of thelipids) and HVJ (35,000 hemagglutinating units) to make the whole volume2 ml.

[0069] SD rats (weighing 400-500 g; purchased from Japan Charles River)were anesthetized with intraperitoneal administration of sodiumpentobarbital (0.1 ml/100 mg), warmed and maintained breathing by anautomated breather. The rats were subjected to thoracotomy at the leftside. The HVJ-liposome-DNA or HVJ-liposome-cont (20 μl) was carefullyinjected directly through the cardiac apex using a 30 G syringe.

Comparative Example 1

[0070] Preparation of HVJ-Liposomes Containing no HGF Expression Vector

[0071] A vector bearing no HGF gene was treated in the same manner asdescribed in Example 1 to prepare the HVJ-liposomes containing no HGFexpression vector. The HGF expression vector-free HVJ-liposomes arehereinafter referred to as HVJ-liposome-cont.

Comparative Example 2

[0072] Preparation of HVJ-Liposomes Containing Human TGF-β ExpressionVector

[0073] HVJ-liposomes containing human TGF-β expression vector wereprepared in a manner similar to Example 1 except for using human TGF-βexpression vector.

[0074] The HVJ-liposomes containing human TGF-expression vector arehereinafter referred to as HVJ-liposome-DNA (TGF-β).

Test Example 1

[0075] Expression of HGF in Rat Coronary Endothelial Cells Sensitizedwith HVJ-Liposome-DNA

[0076] HVJ-liposome-DNA (concentration of the HGF expression vector inliposomes: 10 μg/ml) was sensitized to rat coronary endothelial cells(cell count: 10⁶). HGF production was determined by ELISA. For control,a similar test was conducted using HVJ-liposome-cont. HGF production wasalso determined on the non-sensitized rat coronary endothelial cells(no-treatment group). The results are shown in FIG. 1 (n=6), wherein“HGF” represents the group of rat coronary endothelial cells sensitizedwith HVJ-liposome-DNA.

[0077] As shown in FIG. 1, the rat coronary endothelial cells sensitizedwith HVJ-liposome-DNA produced and secreted HGF on a high level. On theother hand, HGF production was not substantially observed either in theintact group or in the group of the rat coronary endothelial cellssensitized with HVJ-liposome-cont.

[0078] Cell counting in the groups tested reveals that the HGFexpression group showed significantly high cell counts.

Test Example 2

[0079] Effects of the Sensitized HGF Expression Vector on Proliferationof Endothelial Cells

[0080] Human endothelial cells were sensitized with HVJ-liposome-cont.The sensitized cells were incubated in the presence or absence of addedexogenously recombinant human HGF (1, 10 and 100 ng/ml) and a cellgrowth rate (%) was determined. The results are shown in FIG. 2 ((line)graph, n=6), wherein “DSF” represents the group of the endothelial cellssensitized with HVJ-liposome-cont and “HGF” represents shows the groupincubated in the presence of recombinant human HGF in a definiteconcentration (*: P<0.05, **: P<0.01 for DSF).

[0081] The (line) graph shown in FIG. 2 reveals that the growth ofendothelial cells is promoted by the exogenously added HGF.

[0082] The endothelial cells sensitized with HVJ-liposome-DNA(concentration: 10 μg/ml) were similarly incubated, and the increasedcells were counted to determine a cell growth rate (%). For control, theendothelial cells sensitized with HVJ-liposome-cont were also incubated,and the increased cells were counted to determine a cell growth rate(%). The results are shown in FIG. 2 (bar, n=6), wherein “DSF”designates the group of the endothelial cells sensitized withHVJ-liposome-cont, and “HGF” designates the group of the endothelialcells sensitized with HVJ-liposome-DNA (**: P<0.01 for DSF, #: P<0.05for HGF, 100 ng/ml).

[0083] As is noted from the bar shown in FIG. 2, the results reveal thatthe cell growth rate of the HVJ-liposome-DNA-sensitized endothelialcells is markedly higher than that of the control group andsignificantly high even when compared to that of the exogenously addedHGF.

[0084] The aforesaid endothelial cells sensitized with HVJ-liposome-DNAwere incubated in the presence or absence of a rabbit anti-human HGFantibody. The cells increased were counted to determine a cell growthrate. For control, the endothelial cells sensitized withHVJ-liposome-cont were incubated, and the cells increased were countedin a similar manner to determine a cell growth rate. The rabbitanti-human HGF antibody (10 μg/ml) was purified by the method asdescribed in Jpn. J. Cancer Res., 83, 1262-1266 (1992). This antibody iscapable of neutralizing the biological activity of 10 ng/ml in itsconcentration of 10 μg/ml. The anti-human HGF antibody is cross-reactiveonly with human HGF but not with rat HGF, whereas the anti-rat HGFantibody is cross-reactive only with rat HGF but not with human HGF.Normal rabbit serum IgG (10 μg/ml) was used for control.

[0085] The results are shown in FIG. 3 (n=6), wherein “control”designates the group of HVJ-liposome-cont-sensitized endothelial cellsincubated in the presence of IgG control; “HGF” designates the group ofHVJ-liposome-DNA-sensitized endothelial cells incubated in the presenceof IgG control; and “HGFab” designates the group ofHVJ-liposome-DNA-sensitized endothelial cells incubated in the presenceof the rabbit anti-human HGF antibody. The cell growth rate (%) isexpressed in terms of relative % when the growth rate in the controlgroup is made 100 (*: P<0.01 for the control group, # P<0.05 for HGF).As shown in FIG. 3, the growth of HVJ-liposome-DNA-sensitizedendothelial cells was arrested in the presence of the anti-human HGFantibody, and the cell growth rate was thus substantially the same asthat of the control group. These results clearly demonstrate that HGF isthe growth factor of endothelial cells.

Test Example 3

[0086] Effects of the Supernatant of the IncubatedHVJ-Liposome-DNA-Sensitized Rat VSMCs on Rat Coronary Endothelial Cells

[0087] The supernatant from the incubated HVJ-liposome-DNA-sensitizedrat VSMCs were added to the rat coronary endothelial cell culture system(cell count: 10⁵) during the stationary phase. After incubation wasconducted for 3 days, the count of the endothelial cells increased wasexamined. For control, the supernatant of the incubatedHVJ-liposome-cont-sensitized rat VSMCs were treated in the similarmanner as described above, and the endothelial cells increased werecounted as described above. The results are shown in FIG. 4 (n=6),wherein “control” indicates the group added with the supernatant fromthe incubated HVJ-liposome-cont-sensitized rat VSMCs, and “HGF”represents the group added with the supernatant of the incubatedHVJ-liposome-DNA-sensitized rat VSMCs.

[0088] As shown in FIG. 4, a significant increase in the count ofendothelial cells was noted in the group added with the supernatant ofthe incubated HVJ-liposome-DNA-sensitized rat VSMCs.

[0089] The concentration of HGF in the culture supernatant of the ratVSMCs sensitized with HVJ-liposome-DNA or HVJ-liposome-cont as describedabove was assayed by ELISA using an anti-human HGF antibody and ananti-rat HGF antibody. The HGF concentration in the culture supernatantof non-sensitized VSMCs was also assayed (no-treatment group).

[0090] The results obtained using the anti-human HGF antibody and theanti-rat HGF antibody are shown in FIGS. 5 and 6, respectively (n=6 inboth tests). In the figure, “control” designates the group of thesupernatant from the incubated HVJ-liposome-cont-sensitized rat VSMCs;and “HGF” designates the group of the supernatant from the incubatedHVJ-liposome-DNA-sensitized rat VSMCs.

[0091] As shown in FIG. 5, HGF was detected in the supernatant of theHVJ-liposome-DNA-sensitized rat VSMCs, and the HGF concentration wassignificantly higher than that of the control group.

[0092]FIG. 6 also reveals that rat HGF was further detected in thesupernatant of the HVJ-liposome-DNA-sensitized rat VSMCs, and the HGFconcentration was significantly higher than that of the control group.

[0093] As observed in FIGS. 5 and 6, no HGF was present in an amountdetectable by ELISA, in both the supernatants of the intact group andthe control group.

Test Example 4

[0094] Effects of the Supernatant from the IncubatedHVJ-Liposome-DNA-Sensitized Rat Coronary Endothelial Cells on RatCoronary Endothelial Cells

[0095] The supernatant of the incubated HVJ-liposomeDNA-sensitized ratcoronary endothelial cells were added to the rat coronary endothelialcell culture system (cell count: 10⁵) during the stationary phase. Afterincubation for 3 days, the count of the increased endothelial cells wasexamined. For control, the endothelial cells were incubated in thesimilar manner, using the culture supernatant of theHVJ-liposome-cont-sensitized rat coronary endothelial cells, and theincreased endothelial cells were counted. The results are shown in FIG.7, wherein A, B and C represents, respectively, the group added with theculture supernatant of the HVJ-liposome-DNA-sensitized rat coronaryendothelial cells (n=8), the group added with the culture supernatant ofthe HVJ-liposome-cont-sensitized rat coronary endothelial cells (n=8),and the no-treatment group (n=15).

[0096] As shown in FIG. 7, a significant increase in the count ofendothelial cells was noted in the group added with the culturesupernatant of the HVJ-liposomeDNA-sensitized rat coronary endothelialcells, whereas in the control group, the cell count was almost the sameas that of the no-treatment group (control group: 0.117±0.002, group A:0.148±0.03, P<0.01).

[0097] Next, an anti-HGF antibody was added to the culture supernatantof the HVJ-liposome-DNA-sensitized rat coronary endothelial cells. Thecount of increased endothelial cells was examined as described above.The results are shown in FIG. 8 (n=8), wherein A represents the groupadded with the culture supernatant of the HVJ-liposome-DNA-sensitizedrat coronary endothelial cells; B represents the group added with theculture supernatant of the HVJ-liposome-cont-sensitized rat coronaryendothelial cells; C represents the group added with the anti-HGFantibody to the culture supernatant of the HVJ-liposome-DNA-sensitizedrat coronary endothelial cells; and D represents the group added with acontrol antibody to the supernatant from the incubatedHVJ-liposome-DNA-sensitized rat coronary endothelial cells.

[0098] As shown in FIG. 8, A and C, the cell growth promoting activityof the culture supernatant of the HVJ-liposome-DNA-sensitized ratcoronary endothelial cells completely disappeared by adding the anti-HGFantibody thereto. The results reveal that the cell growth promotingactivity of the culture supernatant of the HVJ-liposome-DNA-sensitizedrat coronary endothelial cells is attributed to HGF.

Test Example 5

[0099] Effects of HVJ-Liposome-DNA-Sensitized Human VSMCs on HumanEndothelial Cells

[0100] Human VSMCs were inoculated on a cell culture insert(manufactured by Coaster, pore diameter of 0.45 μm), which were thengrown in DMEM medium supplemented with 10% bovine serum. On the otherhand, human endothelial cells were inoculated on a 6-well plate andmaintained in DMEM medium supplemented with 10% bovine serum. When VSMCswere proliferated to reach 80% confluence, VSMCs were incubated at 4° C.for 5 minutes and at 37° C. for 30 minutes together withHVJ-liposome-DNA (DNA content in the liposomes: 10 μg) or withHVJ-liposome-cont. After sensitization, the insert containing thesensitized VSMCs was added to each well containing human endothelialcells in the stationary phase. VSMCs and the endothelial cells wereco-incubated for 3 days in DMEM medium supplemented with 0.5% bovineserum. Thereafter the cell count was determined with a WST-cell counterkit (manufactured by Wako Co.). The results are shown in FIG. 9 (n=6).In the figure, “control” represents the group co-incubated with theHVJ-liposome-cont-sensitized VSMCs, and “HGF” represents the group ofthe supernatant from the incubated HVJ-liposome-DNA-sensitized VSMCs.

[0101] The results shown in FIG. 9 reveal that human VSMCs sensitizedwith HVJ-liposome-DNA could significantly increase the growth ofnon-sensitized human endothelial cells in the stationary phase.

Test Example 6

[0102] Effects of the HVJ-Liposome-DNA-Sensitized Rat VSMCs on RatCoronary Endothelial Cells

[0103] The HVJ-liposome-DNA-sensitized rat VSMCs (cell count: 106) wereco-incubated for 3 days with rat coronary endothelial cells (cell count:105%) in the stationary phase. Thereafter, the count of the increasedendothelial cells was examined. For control, endothelial cells wereco-incubated in the similar manner using theHVJ-liposome-cont-sensitized rat VSMCs, and the increased endothelialcells were counted. The results are shown in FIG. 10 (n=6), wherein“control” represents the rat VSMCs group sensitized with theHVJ-liposome-DNA, and “HGF” represents the rat VSMCs group sensitizedwith HVJ-liposome-cont.

[0104] As shown in FIG. 10, the growth of the endothelial cells wasstimulated by HGF released from the HVJ-liposome-DNA-sensitized ratVSMCs, and the increased cell count was observed (control group:0.126±0.006, HGF group: 0.156±0.01, P<0.05).

Test Example 7

[0105] Growth of Rat VSMCs Sensitized with HVJ-Liposome-DNA

[0106] Rat VSMCs sensitized with HVJ-liposome-DNA and r at VSMCssensitized with HVJ-liposome-cont were incubated, respectively, to makecomparison of the increased cell count therebetween. Sensitization withHVJ-liposome-DNA did not affect cell growth at all. The results revealthat HGF has no cell growth promoting effect on VSMCs.

Test Example 8

[0107] Induction of Angiogenesis in Rat Heart Muscle Directly Injectedwith HVJ-Liposome-DNA

[0108] Rat heart muscle directly injected with HVJ-liposome-DNA, ratheart muscle directly injected with HVJ-liposome-cont and ratno-treatment heart muscle were stained with HE and Azan, respectively,and examined on a microscope to count the number of microvessels. Theresults are shown in FIG. 11, wherein “HGF” designates the number ofmicrovessels in rat heart muscle directly injected withHVJ-liposome-DNA, and “control” designates the number of microvessels inrat heart muscle directly injected with HVJ-liposome-cont.

[0109] As is noted from FIG. 11, the number of minute blood vesselssignificantly increased in the rat heart muscle injected withHVJ-liposome-DNA, as compared to those of the rat heart muscle injectedwith HVJ-liposome-cont and the rat no-treatment heart muscle. Theseresults reveal that HGF having the activity of growing endothelial cellsexhibits an angiogenesis activity in vivo.

Test Example 9

[0110] Repair of Articular Cartilage by Directly IntroducingHVJ-Liposome-DNA into the Joint

[0111] Ten weeks aged Fischer's rats were injured at the femoralintercondylaris through subcartilage using Kirschner's wires of 1.8 mmin diameter. One week after the operation, the HVJ-liposome-DNA (100μl/knee) prepared in Example 1 was introduced directly into the joint.For control, the HVJ-liposome-cont prepared in Comparative Example 1 andHVJ-liposome-DNA (TGF-β) prepared in Comparative Example 2 wereadministered directly into the joint in the same amount. Rats weresacrificed 1, 3 and 4 weeks after introduction of these genes, etc. andthe repaired sites were histologically observed.

[0112] As shown in FIG. 12, the results indicate that the synthesis ofproteoglycan stained with Toluidine Blue was observed 3 weeks afteradministration of the HVJ-liposome-DNA into the joint, displaying thedevelopment of cartilage-like cells. Furthermore, as shown in FIG. 13, 4weeks after administration of the HVJ-liposome-DNA into the joint, therewas observed a tendency to further extend the area of developingcartilage-like cells, in which the synthesis of proteoglycan wasrecognized.

[0113] As shown in FIG. 14, where the HVJ-liposome-DNA (TGF-β) preparedin Comparative Example 2 was injected into the joint, development ofsuch cartilage-like cells was not observed even 4 weeks after theadministration. Furthermore, as shown in FIG. 15, where theHVJ-liposome-cont prepared in Comparative Example 1 was injected intothe joint, development of such cartilage-like cells was not observedeven 4 weeks after the administration.

INDUSTRIAL APPLICABILITY

[0114] The medicament of the present invention provides persistenttherapeutic effects, as compared to HGF itself. Moreover, the medicamentof the present invention may be topically applied to the target organsso that the effects can be selectively exhibited, resulting inminimizing the side effects of HGF.

What is claimed is:
 1. A medicament comprising a HGF gene.
 2. A liposomecontaining a HGF gene.
 3. A liposome according to claim 2, which is amembrane fusion liposome fused to Sendai virus.
 4. A medicamentcomprising a liposome according to claim 2 or
 3. 5. A medicamentaccording to claim 1 or 4, which is for use in the treatment forarterial diseases.
 6. A medicament according to claim 1 or 4, which isfor use in the treatment for cartilage injury.